40 results
8-K
EX-99.1
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
Exhibit 99.1
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th … -101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society
8-K
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
of the Company’s VISTA blocking immunotherapy, KVA12123, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting. A copy of the press release is attached
8-K
EX-99.1
KA
Kineta Inc
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
Abstract accepted for KVA12123 poster presentation of monotherapy clinical data from VISTA-101 Phase 1/2 clinical trial at Society for Immunotherapy
8-K
EX-99.1
KA
Kineta Inc
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
Exhibit 99.1
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th … -CD27 agonist monoclonal antibodies (mAbs) at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief
8-K
cy2jz3d erf
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.1
11f7cql tc
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
425
gz3kd7rnb dqrg0pnw
29 Nov 22
Business combination disclosure
4:03pm
8-K
EX-99.1
u1ac nhd14sgpd
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
78p4k kwp9vxs
27 Oct 22
Business combination disclosure
7:15am
8-K
f04r81rzrda5vl
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am
8-K
EX-99.1
jc3a1i
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am
425
ckho7u
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.2
6w2 bssl5fhs5gzd
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
s4doul7 093bff
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
iquc68
13 May 21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
4:00pm
8-K
EX-2.1
htu6kay9rfkgokx w6i5
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
425
EX-2.1
a5h9bl3xnw5b67y uj
24 Aug 20
Business combination disclosure
5:28pm
8-K
EX-99.1
ubmj1zb7mnzaxfd
15 May 20
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results
4:11pm